The effect of AOD9604 treatment on IGF-1 levels was of particular interest, since hGH administration is associated with increases in IGF-1 levels. Prolonged increases in IGF-1 may have a variety of undesirable effects, including an increase in cancer risk [22, 23]. In this study the levels of circulating IGF-1 were measured at the baseline visit and at the end of the 12-week treatment period. There was no significant change in the levels of IGF-1 in any of the treatment groups (Table 1).
The prescription form of IGF-1 most often injected is “mecasermin”, which goes by the trade name Increlex. Manufactured using recombinant DNA technology, mecasermin is clinically used to treat IGF-1 deficiency and stunted growth. It is also prescribed to patients who have developed antibody resistance to normal growth hormone therapy. Increlex is actually identical to natural IGF-1, meaning that it has the identical 70 amino acid sequence of IGF-1 that the body produces. In other words, it’s not some kind of growth hormone “precursor”. It’s just straight up IGF-1.
AOD9604, a synthetic fragment of hGH consisting of the amino acid residues 177–191 with the addition of a tyrosine residue to the N-terminus was prepared with solid-phase synthesis procedure and purified with reverse-phase HPLC methodology in our laboratories (13). The structure of the peptide analog was verified with mass spectrometry and amino acid analysis. The hGH was a gift of Professor Michael Waters (University of Queensland, Brisbane, Australia). BRL37344 (β3-AR agonist) was a gift from Dr. Jon Arch (SmithKline Beecham, Harlow, UK).
We organise and run biennial international scientific conferences, satellites and support local state meetings. Our meetings are designed to be in the fashion of the relaxed Gordon conference – with about 200 delegates and with a friendly and a highly participatory atmosphere. We also have a strong commitment to our early career researchers and students.
In laboratory tests on fat cells from rodents, pigs, dogs, and humans, the HGH fragment released fat specifically from obese fat cells but not from lean ones, reduced new fat accumulation in all fat cells, enhanced the burning of fat. In rodents (rats and mice), HGH fragment reduced body fat in obese animals but, enhanced fat burning without changing food consumption or inducing growth (as it does not increase IGF levels) or any other unwanted Growth Hormone effect. Recent research has shown AOD9604 to be an extremely potent and effective fat burner. Metabolic is developing AOD-9604 for the potential treatment of obesity. Research studies have shown that AOD9604 actually acts on the reduction of excessive adipose tissues such as those in the abdominal area, increase in muscle mass, and enhances the lipid content of the body.
Note: If you are a person concerned about loss of muscle mass, you can consume a small amount of protein every 2-3 hours (amino acid tablets such as EAA and BCAA are good for this purpose and can be purchased from any health food shop or ordered online). However there is little reason to be concerned about muscle loss because when fat is available for energy, such as following HGH Frag 176-191 injections, protein and therefore muscle mass are spared.
The β3-AR and actin primers were intron spanning to potentially reveal contaminant genomic DNA (none observed). Reverse primers were labeled before the PCR in a reaction mixture containing 120 pmol oligonucleotide, 70 μCi[γ -33P]ATP (Bresagen, Adelaide, Australia), 1× One-Phor-All Plus buffer (Pharmacia Biotech, Uppsala, Sweden) and 20 U T4 polynucleotide kinase (Pharmacia Biotech) in a volume of 40 μl. Following incubation at 37 C for 30 min, reactions were diluted to 100 μl with H2O and heated at 90 C for 2 min.
Application would result in all current OTC paracetamol/ phenylephrine products being up-scheduled to S3. Applicant’s justification for changing current combination products from exempt or S2 to S3 is on theoretical basis only, and no evidence provided of clinical risk. Pharmacokinetic study found that co-administration of paracetamol with phenylephrine increased plasma phenylephrine levels – applicant says this has potential for cardiac safety risk in susceptible patients.
Ipamorelin stimulates the pituitary gland to produce more endogenous growth hormone. This means your body’s Ipamorelin levels naturally grow, rather than simply adding synthetic growth hormone into your system. This stimulation is much more selective with Ipamorelin, especially compared to older peptides like Sermorelin. For patients, this means Ipamorelin has more benefits with fewer side effects.
Finally, the hexadecapeptide AOD9604 did not induce allergenic reactions when consumed over 24 weeks. Blood of patients was analyzed for the presence of anti-AOD9604 antibody formation at various times and at the end of the studies (latest time point after 24 weeks). In none of the performed studies, at no time, were anti-AOD9604 antibodies detected in serum collected from any subjects in any treatment group.
From the standpoint of protein synthesis and muscle repair, IGF-1 injections have also been shown to enhance the anticatabolic effects of insulin and to increase the protein synthesis normally induced by growth hormone. This is because, like insulin, IGF-1 encourages amino acid uptake into muscle cells, stimulates peripheral tissue uptake of glucose (which lowers blood glucose levels), and suppresses liver glucose production. That last fact is important and is actually why IGF-1 is even being considered as a diabetes-prevention drug. Insulin resistance can cause the liver to produce excess glucose, which then causes even more insulin insensitivity and can eventually result in type II diabetes, and IGF-1 can decrease the need for this type excessive insulin release.
When using any GHRH, it should always be remembered that positive results cannot be achieved overnight. These compounds act steadily over time, and the best results can be achieved slowly, and with a nutritious diet and a proper exercise regime. Also, these peptides are not sex-specific, so they do not have any androgenic effects. They can be used by women in the same dosages that men do.
Ipamorelin is a man-made peptide that is part of the growth hormone family. Rated as one of the safest in the peptide industry, it has strong growth hormone releasing properties. From this, it is a huge winner with athletes and bodybuilders. This is because it builds muscle and keeps weight down quickly. It works by sending signals to the pituitary gland at the base of the brain and adjusts and controls various body functions through the endocrine system. It binds certain receptors inside cells. This allows cells to respond and change, encouraging growth and regulation of hormones. Ipamorelin can help with:
Press coverage and word of mouth has generated quite a bit of hype around AOD9604. Despite its popularity on the black market, there is no research into the safety and effect of injecting this peptide at high doses. Intriguingly, it is not currently in Calzada's interest to fight the black market production of AOD9604, even though it is a patented product. Calzada lack the funds to legitimately boost the reputation of this peptide through clinical trials, and there is a strong chance these would once again prove that AOD9604 has no effect. The good reputation this peptide currently enjoys is likely to provide strong leverage to its marketing as a food supplement in the United States.
Hexarelin: Part of a family of drugs called growth hormone-releasing peptides (GHRP; commonly shortened in media to “peptides”) Hexarelin increases the body’s production of its own human growth hormone, and in so doing may help increase muscle mass and strength. The potential adverse effects of repeated doses of peptides may include various hormonal imbalances in the body. Hexarelin is banned by WADA. –– Benjamin Koh
There were no significant changes in IGF-1 values observed during 24 hours following any AOD9604 dose compared with placebo. No significant differences in glucose levels were observed following AOD9604 administration compared with placebo with the exception of one isolated time point (8% increase 12 hour post treatment in one subject receiving 54 mg AOD09604). There were no clinically significant observable trends in vital signs, physical examinations, abnormalities noted in the ECG measurements, or findings in the safety-related laboratory tests throughout the study.
Figure 1A shows the chronic effect of saline, AOD9604, and hGH in lean C57BL/6J mice on body weight and food intake. The hGH potently increased the body weight gain of these mice, reaching significance by d 8. There was an increase in body weight after AOD9604 only on the last day of treatment. In contrast, ob/ob mice (Fig. 1B) showed a profound decrease in body weight after both AOD9604 and hGH. Importantly, these effects were not attributed to changes in food intake in either the lean or the ob/ob mice (Fig. 1, C and D, respectively).
Over the last 40 years a lot of research has been done on various peptides developing new peptide sequences to produce new peptides with fewer side effects and new beneficial effects. For example fragments of the growth hormone peptide have been developed such as AOD 9604 which possess all the fat burning properties of growth hormone without any of its adverse effects on blood sugar or growth.